Molecular cancer therapeutics

Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.

Molecular cancer therapeutics

More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, Giacomini KM

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Molecular cancer therapeutics

Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Molecular cancer therapeutics

Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.

Molecular cancer therapeutics

Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.

Molecular cancer therapeutics

Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN

Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.

Molecular cancer therapeutics

Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY

Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.

Molecular cancer therapeutics

Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Molecular cancer therapeutics

Li C, Li R, Grandis JR, Johnson DE

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Molecular cancer therapeutics

Li C, Li R, Grandis JR, Johnson DE

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.

Molecular cancer therapeutics

Chen JS, Zhou LJ, Entin-Meer M, Yang X, Donker M, Knight ZA, Weiss W, Shokat KM, Haas-Kogan D, Stokoe D

Pages